Martin Blaser

Dr. Martin Blaser

orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2012 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
ICIlseung Cho
Ilseung Cho
MBMartin Blaser
Martin Blaser

1 April 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JGJack A Gilbert
Jack A Gilbert
MBMartin Blaser
Martin Blaser
JCJ Gregory Caporaso
J Gregory Caporaso
JJJanet K Jansson
Janet K Jansson
SLSusan V Lynch
Susan V Lynch
RKRob Knight
Rob Knight

1 August 2014 in Cell
Verified
Journal Article
Closed access
LCLaura Cox
Laura Cox
SYShingo Yamanishi
Shingo Yamanishi
JSJiho Sohn
Jiho Sohn
AAAlexander Alekseyenko
Alexander Alekseyenko
JLJacqueline M. Leung
Jacqueline M. Leung
MBMartin Blaser
Martin Blaser

15 June 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
NBNicholas A. Bokulich
Nicholas A. Bokulich
JCJennifer Chung
Jennifer Chung
TBThomas Battaglia
Thomas Battaglia
NHNora Henderson
Nora Henderson
MJMelanie Jay
Melanie Jay
MBMartin Blaser
Martin Blaser
A longitudinal study of intestinal microbiota in children and their mothers shows that antibiotics, cesarean section, and infant formula alter patterns of microbial acquisition and succession during the first 2 years of childhood.

18 December 2017 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
PCPaul I. Costea
Paul I. Costea
FHFalk Hildebrand
Falk Hildebrand
MAManimozhiyan Arumugam
Manimozhiyan Arumugam
FBFredrik Bäckhed
Fredrik Bäckhed
MBMartin Blaser
Martin Blaser
PBPeer Bork
Peer Bork

29 April 2016 in Science
Verified
Journal Article
Closed access
PDF file
MBMartin Blaser
Martin Blaser
Anti-infectives, including antibiotics, are essentially different from all other drugs; they not only affect the individual to whom they are given but also the entire community, through selection for resistance to their own action. Thus, their use resides at the intersection of personal and public health. Antibiotics can be likened to a four-edged sword against bacteria. The first two edges of the antibiotic sword were identified immediately after their discovery and deployment in that they not only benefit an individual in treating their infection but also benefit the community in preventing the spread of that infectious agent. The third edge was already recognized by Alexander Fleming in 1945 in his Nobel acceptance speech, which warned about the cost to the community of antibiotic resistance that would inevitably evolve and be selected for during clinical practice. We have seen this cost mount up, as resistance curtails or precludes the activities of some of our most effective drugs for clinically important infections. But the fourth edge of the antibiotic sword remained unappreciated until recently, i.e., the cost that an antibiotic exerts on an individual’s own health via the collateral damage of the drug on bacteria that normally live on or in healthy humans: our microbiota. These organisms, their genes, metabolites, and interactions with one another, as well as with their host collectively, represent our microbiome. Our relationship with these symbiotic bacteria is especially important during the early years of life, when the adult microbiome has not yet formed.